Measure Cell Death and Viability in One Easy Step!
We're excited to feature our aCella Tox Bioluminescent Cytotoxicity Assay! Our aCella Tox kit works by quantitatively measuring cytotoxicity and cell viability on the same plate. The assay measures the release of Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) from both mammalian and bacterial cells.
Learn more about our aCella Tox Assay Kit!
Assay Principle:
Glycolytic glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a multifunctional protein that can also mediate cell death under oxidative stress (Nakajima et. al., 2017). The release of GAPDH coupled with the enzymatic activity of 2-Phosphoglyceric Phosphokinase (PGK) leads to ATP production. Our aCella Tox kit detects this activity via luciferase/luciferin bioluminescence methodology producing light.
Advantages of Using this Kit:
- Versatile - aCella Tox can measure activity in a variety of cells (T cells, primary cells, NK cells, bacterial cells)
- Assay can run in the presence of serum or phenol red present in media
- Highly sensitive - aCella Tox can detect fewer than 500 cells/well in the presence of serum
- Adaptable for high throughput formats
- Non-destructive assay that allows monitoring of multiple parameters
- Non-radioactive and can be used to efficiently and accurately measure Antibody Mediated Cellular Toxicity (ADCC), Cellular Mediated Toxicity (CMC) and Complement Dependent Cytotoxicity (CDC)
Our aCella Tox kit is available in multiple sizes:
- 1000 tests (without plates)
- 500 tests (without plates)
- 500 tests (with 5 Lumi plates + 5 TC plates)
- 500 tests (with 5 Lumi plates)
Also available to order in bulk - contact us for a quote!
If you have additional inquiries, our technical support team is ready to help!
Learn more about our Cell Viability portfolio.
Discover the advantages of our Cell Viability portfolio.
Related Services:
ADCC, CDC, and CMC Services - we provide ADCC/CDC assay services to determine the activity of the antibody and/or complement against a specified target cell line.
